Skip to main content Skip to section navigation Skip to footer
  • For Physicians
  • For Patients
  • For Distributors
  • Investors
  • For Physicians
  • For Patients
  • For Distributors
  • Investors
IceCure
  • Clinical Applications
    • Breast Tumors
    • Kidney Cancer
    • Lung Cancer
    • Palliative Care
    • Fibroadenomas
  • Products
    • ProSense
    • User Manuals
  • Technology
  • Resources
    • Publications
    • Case Studies
    • Webinars
    • Videos
    • Blog
    • Media & Events
    • ICE3 Trial
  • Company
    • About Us
    • Careers
  • Contact
Menu
  • Clinical Applications
    • Breast Tumors
    • Kidney Cancer
    • Lung Cancer
    • Palliative Care
    • Fibroadenomas
  • Products
    • ProSense
    • User Manuals
  • Technology
  • Resources
    • Publications
    • Case Studies
    • Webinars
    • Videos
    • Blog
    • Media & Events
    • ICE3 Trial
  • Company
    • About Us
    • Careers
  • Contact
  • Clinical Applications
    • Breast Tumors
    • Kidney Cancer
    • Lung Cancer
    • Palliative Care
    • Fibroadenomas
  • Products
    • ProSense
    • User Manuals
  • Technology
  • Resources
    • Publications
    • Case Studies
    • Webinars
    • Videos
    • Blog
    • Media & Events
    • ICE3 Trial
  • Company
    • About Us
    • Careers
  • Contact
  • For Physicians
  • For Patients
  • For Distributors
  • Investors
Menu
  • Clinical Applications
    • Breast Tumors
    • Kidney Cancer
    • Lung Cancer
    • Palliative Care
    • Fibroadenomas
  • Products
    • ProSense
    • User Manuals
  • Technology
  • Resources
    • Publications
    • Case Studies
    • Webinars
    • Videos
    • Blog
    • Media & Events
    • ICE3 Trial
  • Company
    • About Us
    • Careers
  • Contact
  • For Physicians
  • For Patients
  • For Distributors
  • Investors

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Company Profile
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Nov 28, 2023 8:00 am EST

IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate

Nov 15, 2023 8:00 am EST

IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights

Nov 15, 2023 7:30 am EST

IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer

Nov 08, 2023 8:00 am EST

IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023

Nov 06, 2023 8:00 am EST

Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System

Nov 03, 2023 4:00 pm EDT

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 30, 2023 8:00 am EDT

IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured in a Presentation at BISICON 2023 in India

Oct 25, 2023 8:00 am EDT

Independent Scientific Paper by Doctors Using IceCure's ProSense® Published in Journal of Breast Imaging Presents Advantages of Cryoablation Breast Conserving Over Surgery in Early Breast Cancer Patients

Oct 05, 2023 8:00 am EDT

Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%

Oct 02, 2023 8:00 am EDT

Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
  • Sitemap
IceCure

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

Facebook-f Tiktok Twitter Linkedin-in Instagram Youtube
© 2025 All Rights Reserved IceCure Medical
Facebook-f Tiktok Twitter Linkedin-in Instagram Youtube
Branding by Titan
Terms of Use    |    Privacy    |    Last Updated: April 9, 2023

We use cookies to offer you a better browsing experience, including personalized advertising. By continuing to use the site you agree to their use.